We are live on ! Find out more

Vera Therapeutics

VERA

Market cap $2.46B

34.19 USD

-0.41

1.18%

At close Updated Aug 28, 4:00 PM EDT

Pre-market

After hours

33.91

-0.28

0.82%

1 day

-1.18%

5 days

6.02%

1 month

2.61%

3 months

-4.66%

6 months

-15.41%

Year to date

-29.68%

1 year

53.39%

5 years

131.01%

10 years

197.3%

About: Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

Employees: 361

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 28.6%

Neutral 71.4%

Negative 0%

Vera Therapeutics: FDA's eGFR Analysis Supports A Speculative Buy

Vera Therapeutics is upgraded to Buy following TRUTAKNA's FDA approval and encouraging eGFR data. The FDA's exploratory eGFR analysis shows stable kidney function with TRUTAKNA, supporting the bull case ahead of full phase 3 data in Q3 2026. TRUTAKNA faces competition from Otsuka's VOYXACT and Vertex's povetacicept but enjoys a commercial head start and broad label.

Vera Therapeutics: FDA's eGFR Analysis Supports A Speculative Buy

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on August 3, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 63,011 shares of Class A common stock and restricted stock units (RSUs) underlying 44,987 shares of Class A common stock to Nancy Bowman, M.D.

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets Launch

Vera Therapeutics NASDAQ: VERA said the U.S. Food and Drug Administration granted accelerated approval to TRUTAKNA, or atacicept-vymj, for adults with primary IgA nephropathy at risk for disease progression.

Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets Launch

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., July 10, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on July 6, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 32,100 shares of Class A common stock and restricted stock units (RSUs) underlying 16,050 shares of Class A common stock to eight (8) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan).

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner

BRISBANE, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced a planned transition of the Chief Regulatory Officer position.

Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner

Vera Therapeutics, Inc. (VERA) Discusses Accelerated FDA Approval of TRUTAKNA for IgA Nephropathy Transcript

Vera Therapeutics, Inc. (VERA) Discusses Accelerated FDA Approval of TRUTAKNA for IgA Nephropathy Transcript

Vera Therapeutics, Inc. (VERA) Discusses Accelerated FDA Approval of TRUTAKNA for IgA Nephropathy Transcript

US FDA approves Vera's kidney disease drug

The U.S. Food and Drug Administration ‌has approved Vera Therapeutics' drug to treat patients with a potentially life-threatening kidney disease, the regulator said ⁠on Tuesday, sending its shares up 6.2% in afternoon trading.

US FDA approves Vera's kidney disease drug

Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy

TRUTAKNA is the first and only available therapy that binds both B-cell activating factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), addressing the immunological drivers at the source of IgA nephropathy (IgAN).1,2 The TRUTAKNA dose is 150 mg injected subcutaneously once weekly, self-administered via an autoinjector by patients at home.1 Investor webcast is scheduled for July 7 at 4:30 pm EDT. A Media Snippet accompanying this announcement is available by clicking on this link.

Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy

What's Going on with Vera Therapeutics Stock on Monday?

Investors are closely watching Vera Therapeutics Inc. (NASDAQ:VERA) as the company awaits the U.S. Food and Drug Administration (FDA) decision for its rare kidney disease drug.

What's Going on with Vera Therapeutics Stock on Monday?

3 Biotech Firms With Major Potential Catalysts in the Coming Months

As Big Pharma braces for a looming patent cliff that threatens billions in revenue, a different group of companies is chasing the opposite story: a single breakthrough that could define their future. For these smaller players, one strong trial readout or FDA approval can mean the difference between a breakout and a bust.

3 Biotech Firms With Major Potential Catalysts in the Coming Months

See News Rankings

Price charts implemented using Lightweight Charts™